› Forums › General Melanoma Community › Upcoming conference for patients & advocates to learn about/discuss personalized medicine
- This topic has 15 replies, 3 voices, and was last updated 11 years, 4 months ago by
Cooper.
- Post
-
- January 14, 2014 at 10:32 pm
Hello all,
I represent Cancer Commons, a nonprofit partner of the MRF. We aim to give patients the information they need to make the best possible treatment decisions with their care team. As part of our efforts, we're co-hosting a special program for patients and advocates at the 2014 Personalized Medicine World Conference in Silicon Valley, CA, Jan 27-28.
If you are curious about how things like molecular testing and targeted therapy are changing the treatment option landscape for patients, please join us! You will be able to learn about and discuss these and other personalized medicine topics with other patients, advocates, doctors and researchers.
Registration is available at a generously discounted fee ($100 down from $1500). Learn more about the program, topics and speakers here: http://2014sv.pmwcintl.com/patients1.php
Happy to answer any questions!
Sarah – Associate Editor at Cancer Commons
- Replies
-
-
- January 15, 2014 at 7:32 pm
Really!? $100 discount? Plus you have to pay travel and lodging? A non profit charging patients $1400 to attend something they can learn elsewhere? What is the fee going to? I don't trust this.
-
- January 15, 2014 at 8:09 pm
I think they mean that the registration fee is $100 but their wording is definitely unclear.
This is not a conference for patients. It is a conference sponsored by a venture capital firm to get scientists/inventors together with potential investors. So, for example, a scientist says she has a great new method to detect melanoma via a blood test. All she needs is $4,000,000 to get it though FDA approval and into commercial production. Might be a great investment, might be a bust.
If you're in town and curious about what is being imagined, this might be fun.
-
- January 15, 2014 at 8:09 pm
I think they mean that the registration fee is $100 but their wording is definitely unclear.
This is not a conference for patients. It is a conference sponsored by a venture capital firm to get scientists/inventors together with potential investors. So, for example, a scientist says she has a great new method to detect melanoma via a blood test. All she needs is $4,000,000 to get it though FDA approval and into commercial production. Might be a great investment, might be a bust.
If you're in town and curious about what is being imagined, this might be fun.
-
- January 15, 2014 at 9:42 pm
And they dont' even mention melanoma in the program, guess it is "others"
When I see Cancer Treatment Centers of America as a sponsor I get worried. Not too many of the top institutions or pharmas are sponsors. Don't fall for it, they want your data!
-
- January 15, 2014 at 9:42 pm
And they dont' even mention melanoma in the program, guess it is "others"
When I see Cancer Treatment Centers of America as a sponsor I get worried. Not too many of the top institutions or pharmas are sponsors. Don't fall for it, they want your data!
-
- January 15, 2014 at 9:42 pm
And they dont' even mention melanoma in the program, guess it is "others"
When I see Cancer Treatment Centers of America as a sponsor I get worried. Not too many of the top institutions or pharmas are sponsors. Don't fall for it, they want your data!
-
- January 15, 2014 at 8:09 pm
I think they mean that the registration fee is $100 but their wording is definitely unclear.
This is not a conference for patients. It is a conference sponsored by a venture capital firm to get scientists/inventors together with potential investors. So, for example, a scientist says she has a great new method to detect melanoma via a blood test. All she needs is $4,000,000 to get it though FDA approval and into commercial production. Might be a great investment, might be a bust.
If you're in town and curious about what is being imagined, this might be fun.
Tagged: cutaneous melanoma
- You must be logged in to reply to this topic.